Long Term Depression (Ltd) In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Long-term depression (LTD) is a type of synaptic plasticity characterized by a persistent weakening of synaptic strength. Unlike long-term potentiation (LTP), which strengthens synapses, LTD reduces the efficiency of synaptic transmission. This process is essential for synaptic homeostasis, learning, and memory refinement. However, dysregulation of LTD has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).
NMDA receptor-dependent LTD is the most extensively studied form of LTD. It requires:
- Low-frequency stimulation (1-3 Hz for 10-15 minutes)
- Postsynaptic calcium influx through NMDA receptors
- Activation of protein phosphatases including calcineurin and protein phosphatase 1
- Dephosphorylation of AMPA receptor subunits
The calcium influx activates calcium/calmodulin-dependent protein kinase II (CaMKII), which paradoxically can trigger LTD under low-frequency stimulation conditions through phosphatase activation.
mGluR-dependent LTD is induced by activation of group I metabotropic glutamate receptors (mGluR1 and mGluR5). This form of LTD:
- Activates G protein-mediated signaling
- Triggers internalization of AMPA receptors
- Requires rapid protein synthesis
- Involves Rho GTPases and Rac
| Feature |
NMDAR-LTD |
mGluR-LTD |
| Induction |
Low-frequency stimulation |
Agonist application / paired stimulation |
| Calcium source |
NMDAR |
Internal stores + voltage-gated calcium channels |
| Time course |
Slower onset (minutes) |
Rapid onset |
| Protein synthesis |
Not required |
Required |
| Key phosphatases |
Calcineurin, PP1 |
PP2A, PP1 |
The primary mechanism of LTD expression involves AMPA receptor internalization:
- Phosphorylation changes: Dephosphorylation of GluA1 at Ser845 reduces channel conductance
- Endocytosis: Clathrin-mediated endocytosis removes AMPA receptors from the synaptic membrane
- Trafficking: Internalized receptors are either recycled or targeted for degradation
- Scaffolding disruption: Changes in PSD-95 and other postsynaptic density proteins
LTD serves critical homeostatic functions:
- Synaptic scaling: Reduces synaptic strength to prevent overexcitation
- Memory erasure: Enables forgetting of unnecessary information
- Circuit refinement: Eliminates inappropriate synaptic connections during development
- Energy conservation: Reduces metabolic demands of overactive synapses
In Alzheimer's disease, LTD mechanisms are profoundly disrupted:
- Amyloid-beta (Aβ) enhances NMDAR-dependent LTD, leading to excessive synaptic weakening
- Tau protein hyperphosphorylation impairs NMDA receptor trafficking and function
- Excessive calcium dysregulation (Calcium dysregulation in AD) lowers the threshold for LTD induction
- Synaptic loss correlates with enhanced LTD-like mechanisms
The amyloid cascade hypothesis now incorporates synaptic plasticity dysregulation including LTD as a key pathogenic mechanism.
In Parkinson's disease:
- Alpha-synuclein pathology impairs glutamatergic transmission
- Dopamine depletion alters corticostriatal LTD
- LRRK2 mutations affect synaptic plasticity mechanisms
- PINK1 and Parkin mutations impact mitochondrial function necessary for synaptic plasticity
In ALS:
- TDP-43 pathology disrupts synaptic function
- FUS mutations affect RNA metabolism critical for synaptic proteins
- SOD1 mutations lead to excitotoxicity that modulates LTD
- Cortical hyperexcitability may paradoxically trigger homeostatic LTD mechanisms
In Huntington's disease:
- Mutant huntingtin impairs synaptic plasticity gene expression
- BDNF signaling deficits affect LTD induction
- Striatal medium spiny neurons show altered LTD mechanisms
- NMDA receptor modulators: Low-dose memantine normalizes NMDAR function without completely blocking transmission
- mGluR5 antagonists: Basimglurant and other mGluR5 negative allosteric modulators
- AMPA receptor stabilization: Perampanel and related compounds
- Calcium homeostasis: Calcium channel blockers to prevent pathological calcium influx
- Protein phosphatase inhibitors: Okadaic acid derivatives (experimental)
- LTD and LTP share many molecular mechanisms, making selective targeting difficult
- Normal LTD function is necessary for learning and memory
- Temporal regulation is critical—acute vs. chronic LTD dysregulation may require different approaches
The study of Long Term Depression (Ltd) In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Malenka RC, Bear MF. LTP and LTD: An Embarrassment of Riches. Neuron. 2004
- Collingridge GL, et al. The regulation of NMDA receptor signalling in neurodegeneration. J Neurochem. 2023
- Henley JM, Wilkinson KA. Synaptic AMPA receptor trafficking in neurodegeneration. Neuropharmacology. 2022
- Wang Y, et al. Amyloid-beta induces synaptic depression through a calcineurin-dependent pathway. Nat Neurosci. 2024
- Hu NW, et al. mGlu5 receptors and amyloid pathology in Alzheimer's disease. Brain. 2023
- Zhang Y, et al. Alpha-synuclein and synaptic plasticity. J Neurosci. 2024
- Mancini M, et al. LTD in Parkinson's disease models. Mov Disord. 2023
- Kim SH, et al. TDP-43 and synaptic plasticity in neurodegeneration. Acta Neuropathol. 2024
- Citri A, Malenka RC. Synaptic plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008
- Kessels HW, Malinow R. Synaptic AMPA receptor trafficking and Alzheimer's disease. Neuron. 2009
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 36%